September 30, 2022
2 min read
Source/Disclosures
Published by:
Disclosures:
Ghusn reports no relevant financial disclosures. Please see the study for all other authors’ relevant financial disclosures.
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
In real-world data from adults with overweight or obesity, weekly semaglutide therapy of 1.7 mg or 2.4 mg was effective at 3 and 6 months for weight loss amounts similar to those observed in clinical trials, according to researchers.
However, those with type 2 diabetes lost a smaller percentage of body weight compared with those without diabetes, researchers reported in the study published in JAMA Network Open.
Weekly semaglutide therapy of 1.7 mg or 2.4 mg is associated with weight loss at 3 and 6 months. Data were derived from Ghusn W, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.31982.
“The Semaglutide Treatment Effect in People with Obesity (STEP) trials have shown the efficacy of semaglutide for the treatment of obesity. In large randomized controlled trials, patients receiving semaglutide 2.4 mg lost a mean of 6% of their weight by week 12 and 12% of their weight by week 28,” Wissam Ghusn, MD, postdoctoral research fellow from the division of gastroenterology and hepatology of the Precision Medicine for Obesity Laboratory at Mayo Clinic in Rochester, Minnesota, and colleagues wrote. “To our knowledge, no retrospective studies have been conducted to assess the effectiveness of semaglutide at the doses used to treat obesity (ie, 1.7 and 2.4 mg).”
Researchers conducted a cohort study at a referral center for weight management and included 175 patients (mean age, 49.3 years; 75.4% women; 88% white; mean BMI, 41.3 kg/m2) with overweight (n = 5) or obesity with data on semaglutide (Wegovy, Novo Nordisk) use collected between January 2021 and March 2022. All patients were followed …….